drugset / Trial / NCT04264819

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

NCT04264819

Phase 3 Completed 295 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.

Timeline

Start
2020-12-14
Primary completion
2022-10-05
Completion
2023-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brolucizumab Other / unclassified 6 mg